These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24340569)

  • 1. Objectivity of reimbursement decisions - does it always has to pay off?
    Kolasa K
    Przegl Epidemiol; 2013; 67(3):503-7, 599-603. PubMed ID: 24340569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are pricing and reimbursement decision-making criteria aligned with public preferences regarding allocation principles in the Polish healthcare sector?
    Kolasa K
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):751-62. PubMed ID: 25052370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of budget impact in drug reimbursement decisions.
    Cohen JP; Stolk E; Niezen M
    J Health Polit Policy Law; 2008 Apr; 33(2):225-47. PubMed ID: 18325899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
    Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
    Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reimbursement and value-based pricing: stratified cost-effectiveness analysis may not be the last word.
    Hawkins N; Scott DA
    Health Econ; 2011 Jun; 20(6):688-98. PubMed ID: 20568075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The costs of heart failure in Poland from the public payer's perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of care: POLKARD.
    Czech M; Opolski G; Zdrojewski T; Dubiel JS; Wizner B; Bolisęga D; Fedyk-Łukasik M; Grodzicki T
    Kardiol Pol; 2013; 71(3):224-32. PubMed ID: 23575775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-part payments for the reimbursement of investments in health technologies.
    Levaggi R; Moretto M; Pertile P
    Health Policy; 2014 Apr; 115(2-3):230-6. PubMed ID: 24268054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restrictions on the reimbursement policy with regard to retail marketing of medicinal products in Poland.
    Zimmermann A
    Acta Pol Pharm; 2013; 70(2):339-43. PubMed ID: 23614291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramsey waits: allocating public health service resources when there is rationing by waiting.
    Gravelle H; Siciliani L
    J Health Econ; 2008 Sep; 27(5):1143-54. PubMed ID: 18468707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The 'Myozyme' decision of the Federal Supreme Court of Switzerland and German Law: a constitutional rights and health insurance law perspective].
    Huster S; Bohmeier A
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(6):443-8. PubMed ID: 22857732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Decision-analytical modelling of costs per QALY in the context of the German Social Law].
    Rogowski WH; Landauer M; John J
    Gesundheitswesen; 2009 Nov; 71(11):739-50. PubMed ID: 19551622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. To survive is not enough. Quality of life in CKD--the need for a new generation of health-oriented economists.
    De Santo NG; De Santo RM; Perna AF; Anastasio P; Bilancio G; Pollastro RM; Di Leo VA; Cirillo M
    J Nephrol; 2008; 21 Suppl 13():S32-50. PubMed ID: 18446731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic value of out-of-hospital emergency care: a structured literature review.
    Lerner EB; Maio RF; Garrison HG; Spaite DW; Nichol G
    Ann Emerg Med; 2006 Jun; 47(6):515-24. PubMed ID: 16713777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Political decisions and implementation: efficient management of a psychiatric department be successful despite working time law, practice fee and other innovations?].
    Wittmund B
    Psychiatr Prax; 2005 Apr; 32(3):153-4. PubMed ID: 15818523
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012-2014.
    Malinowski KP; Kawalec P; Trąbka W
    Health Policy; 2016 Nov; 120(11):1249-1255. PubMed ID: 27884491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of the 2011 Reimbursement Act in Poland: Desired and undesired effects of the changes in reimbursement policy.
    Kawalec P; Sagan A; Stawowczyk E; Kowalska-Bobko I; Mokrzycka A
    Health Policy; 2016 Apr; 120(4):356-61. PubMed ID: 26994865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries.
    Orlewska E; Mierzejewski P
    Value Health; 2004; 7(1):1-10. PubMed ID: 14720125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
    Delwel GO; Sprenger MJ
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.